nodes	percent_of_prediction	percent_of_DWPC	metapath
Naratriptan—migraine—Prednisone—prostate cancer	0.668	1	CpDpCtD
Naratriptan—Eletriptan—CYP2A6—prostate cancer	0.000666	0.22	CrCbGaD
Naratriptan—Almotriptan—CYP2E1—prostate cancer	0.000607	0.201	CrCbGaD
Naratriptan—Almotriptan—CYP2C19—prostate cancer	0.000601	0.199	CrCbGaD
Naratriptan—Eletriptan—CYP2C19—prostate cancer	0.000468	0.155	CrCbGaD
Naratriptan—Almotriptan—CYP3A4—prostate cancer	0.000382	0.126	CrCbGaD
Naratriptan—Eletriptan—CYP3A4—prostate cancer	0.000298	0.0985	CrCbGaD
Naratriptan—Confusional state—Docetaxel—prostate cancer	6.72e-05	0.000267	CcSEcCtD
Naratriptan—Anxiety—Capecitabine—prostate cancer	6.71e-05	0.000266	CcSEcCtD
Naratriptan—Photosensitivity reaction—Doxorubicin—prostate cancer	6.68e-05	0.000265	CcSEcCtD
Naratriptan—Oedema—Docetaxel—prostate cancer	6.67e-05	0.000265	CcSEcCtD
Naratriptan—Anaphylactic shock—Docetaxel—prostate cancer	6.67e-05	0.000265	CcSEcCtD
Naratriptan—Discomfort—Capecitabine—prostate cancer	6.65e-05	0.000264	CcSEcCtD
Naratriptan—Vision blurred—Prednisone—prostate cancer	6.64e-05	0.000264	CcSEcCtD
Naratriptan—Infection—Docetaxel—prostate cancer	6.62e-05	0.000263	CcSEcCtD
Naratriptan—Sinusitis—Epirubicin—prostate cancer	6.62e-05	0.000263	CcSEcCtD
Naratriptan—Feeling abnormal—Etoposide—prostate cancer	6.61e-05	0.000263	CcSEcCtD
Naratriptan—Hyperglycaemia—Doxorubicin—prostate cancer	6.6e-05	0.000262	CcSEcCtD
Naratriptan—Diarrhoea—Mitoxantrone—prostate cancer	6.6e-05	0.000262	CcSEcCtD
Naratriptan—Dry mouth—Capecitabine—prostate cancer	6.59e-05	0.000262	CcSEcCtD
Naratriptan—Vomiting—Estradiol—prostate cancer	6.58e-05	0.000261	CcSEcCtD
Naratriptan—Pneumonia—Doxorubicin—prostate cancer	6.56e-05	0.000261	CcSEcCtD
Naratriptan—Shock—Docetaxel—prostate cancer	6.56e-05	0.00026	CcSEcCtD
Naratriptan—Nervous system disorder—Docetaxel—prostate cancer	6.54e-05	0.00026	CcSEcCtD
Naratriptan—Ill-defined disorder—Prednisone—prostate cancer	6.54e-05	0.00026	CcSEcCtD
Naratriptan—Thrombocytopenia—Docetaxel—prostate cancer	6.53e-05	0.000259	CcSEcCtD
Naratriptan—Rash—Estradiol—prostate cancer	6.53e-05	0.000259	CcSEcCtD
Naratriptan—Drowsiness—Doxorubicin—prostate cancer	6.52e-05	0.000259	CcSEcCtD
Naratriptan—Dermatitis—Estradiol—prostate cancer	6.52e-05	0.000259	CcSEcCtD
Naratriptan—Anaemia—Prednisone—prostate cancer	6.51e-05	0.000259	CcSEcCtD
Naratriptan—Confusional state—Capecitabine—prostate cancer	6.51e-05	0.000258	CcSEcCtD
Naratriptan—Headache—Estradiol—prostate cancer	6.49e-05	0.000258	CcSEcCtD
Naratriptan—Skin disorder—Docetaxel—prostate cancer	6.48e-05	0.000257	CcSEcCtD
Naratriptan—Agitation—Prednisone—prostate cancer	6.47e-05	0.000257	CcSEcCtD
Naratriptan—Oedema—Capecitabine—prostate cancer	6.46e-05	0.000256	CcSEcCtD
Naratriptan—Bradycardia—Epirubicin—prostate cancer	6.44e-05	0.000256	CcSEcCtD
Naratriptan—Infection—Capecitabine—prostate cancer	6.41e-05	0.000255	CcSEcCtD
Naratriptan—Neuropathy peripheral—Doxorubicin—prostate cancer	6.4e-05	0.000254	CcSEcCtD
Naratriptan—Urticaria—Etoposide—prostate cancer	6.37e-05	0.000253	CcSEcCtD
Naratriptan—Haemoglobin—Epirubicin—prostate cancer	6.36e-05	0.000253	CcSEcCtD
Naratriptan—Malaise—Prednisone—prostate cancer	6.35e-05	0.000252	CcSEcCtD
Naratriptan—Shock—Capecitabine—prostate cancer	6.35e-05	0.000252	CcSEcCtD
Naratriptan—Body temperature increased—Etoposide—prostate cancer	6.34e-05	0.000252	CcSEcCtD
Naratriptan—Nervous system disorder—Capecitabine—prostate cancer	6.33e-05	0.000251	CcSEcCtD
Naratriptan—Vertigo—Prednisone—prostate cancer	6.33e-05	0.000251	CcSEcCtD
Naratriptan—Haemorrhage—Epirubicin—prostate cancer	6.33e-05	0.000251	CcSEcCtD
Naratriptan—Thrombocytopenia—Capecitabine—prostate cancer	6.32e-05	0.000251	CcSEcCtD
Naratriptan—Syncope—Prednisone—prostate cancer	6.32e-05	0.000251	CcSEcCtD
Naratriptan—Hypoaesthesia—Epirubicin—prostate cancer	6.3e-05	0.00025	CcSEcCtD
Naratriptan—Skin disorder—Capecitabine—prostate cancer	6.27e-05	0.000249	CcSEcCtD
Naratriptan—Sweating—Doxorubicin—prostate cancer	6.26e-05	0.000248	CcSEcCtD
Naratriptan—Hyperhidrosis—Capecitabine—prostate cancer	6.24e-05	0.000248	CcSEcCtD
Naratriptan—Hypotension—Docetaxel—prostate cancer	6.23e-05	0.000247	CcSEcCtD
Naratriptan—Loss of consciousness—Prednisone—prostate cancer	6.19e-05	0.000246	CcSEcCtD
Naratriptan—Nausea—Estradiol—prostate cancer	6.15e-05	0.000244	CcSEcCtD
Naratriptan—Vomiting—Mitoxantrone—prostate cancer	6.13e-05	0.000244	CcSEcCtD
Naratriptan—Sinusitis—Doxorubicin—prostate cancer	6.12e-05	0.000243	CcSEcCtD
Naratriptan—Convulsion—Prednisone—prostate cancer	6.1e-05	0.000242	CcSEcCtD
Naratriptan—Rash—Mitoxantrone—prostate cancer	6.08e-05	0.000242	CcSEcCtD
Naratriptan—Dermatitis—Mitoxantrone—prostate cancer	6.08e-05	0.000241	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.07e-05	0.000241	CcSEcCtD
Naratriptan—Headache—Mitoxantrone—prostate cancer	6.04e-05	0.00024	CcSEcCtD
Naratriptan—Hypotension—Capecitabine—prostate cancer	6.03e-05	0.00024	CcSEcCtD
Naratriptan—Myalgia—Prednisone—prostate cancer	6e-05	0.000238	CcSEcCtD
Naratriptan—Arthralgia—Prednisone—prostate cancer	6e-05	0.000238	CcSEcCtD
Naratriptan—Paraesthesia—Docetaxel—prostate cancer	5.99e-05	0.000238	CcSEcCtD
Naratriptan—Anxiety—Prednisone—prostate cancer	5.98e-05	0.000237	CcSEcCtD
Naratriptan—Bradycardia—Doxorubicin—prostate cancer	5.96e-05	0.000237	CcSEcCtD
Naratriptan—Dyspnoea—Docetaxel—prostate cancer	5.94e-05	0.000236	CcSEcCtD
Naratriptan—Somnolence—Docetaxel—prostate cancer	5.93e-05	0.000235	CcSEcCtD
Naratriptan—Discomfort—Prednisone—prostate cancer	5.93e-05	0.000235	CcSEcCtD
Naratriptan—Hypersensitivity—Etoposide—prostate cancer	5.91e-05	0.000235	CcSEcCtD
Naratriptan—Tinnitus—Epirubicin—prostate cancer	5.9e-05	0.000234	CcSEcCtD
Naratriptan—Haemoglobin—Doxorubicin—prostate cancer	5.89e-05	0.000234	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Capecitabine—prostate cancer	5.88e-05	0.000234	CcSEcCtD
Naratriptan—Cardiac disorder—Epirubicin—prostate cancer	5.88e-05	0.000233	CcSEcCtD
Naratriptan—Haemorrhage—Doxorubicin—prostate cancer	5.86e-05	0.000233	CcSEcCtD
Naratriptan—Hypoaesthesia—Doxorubicin—prostate cancer	5.83e-05	0.000231	CcSEcCtD
Naratriptan—Paraesthesia—Capecitabine—prostate cancer	5.8e-05	0.00023	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Docetaxel—prostate cancer	5.76e-05	0.000229	CcSEcCtD
Naratriptan—Asthenia—Etoposide—prostate cancer	5.76e-05	0.000229	CcSEcCtD
Naratriptan—Dyspnoea—Capecitabine—prostate cancer	5.76e-05	0.000229	CcSEcCtD
Naratriptan—Anaphylactic shock—Prednisone—prostate cancer	5.75e-05	0.000228	CcSEcCtD
Naratriptan—Oedema—Prednisone—prostate cancer	5.75e-05	0.000228	CcSEcCtD
Naratriptan—Fatigue—Docetaxel—prostate cancer	5.75e-05	0.000228	CcSEcCtD
Naratriptan—Angiopathy—Epirubicin—prostate cancer	5.74e-05	0.000228	CcSEcCtD
Naratriptan—Nausea—Mitoxantrone—prostate cancer	5.73e-05	0.000228	CcSEcCtD
Naratriptan—Immune system disorder—Epirubicin—prostate cancer	5.72e-05	0.000227	CcSEcCtD
Naratriptan—Infection—Prednisone—prostate cancer	5.71e-05	0.000227	CcSEcCtD
Naratriptan—Constipation—Docetaxel—prostate cancer	5.7e-05	0.000226	CcSEcCtD
Naratriptan—Pain—Docetaxel—prostate cancer	5.7e-05	0.000226	CcSEcCtD
Naratriptan—Chills—Epirubicin—prostate cancer	5.68e-05	0.000226	CcSEcCtD
Naratriptan—Pruritus—Etoposide—prostate cancer	5.68e-05	0.000225	CcSEcCtD
Naratriptan—Shock—Prednisone—prostate cancer	5.66e-05	0.000225	CcSEcCtD
Naratriptan—Arrhythmia—Epirubicin—prostate cancer	5.66e-05	0.000225	CcSEcCtD
Naratriptan—Nervous system disorder—Prednisone—prostate cancer	5.64e-05	0.000224	CcSEcCtD
Naratriptan—Alopecia—Epirubicin—prostate cancer	5.59e-05	0.000222	CcSEcCtD
Naratriptan—Skin disorder—Prednisone—prostate cancer	5.59e-05	0.000222	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Capecitabine—prostate cancer	5.57e-05	0.000221	CcSEcCtD
Naratriptan—Fatigue—Capecitabine—prostate cancer	5.57e-05	0.000221	CcSEcCtD
Naratriptan—Hyperhidrosis—Prednisone—prostate cancer	5.56e-05	0.000221	CcSEcCtD
Naratriptan—Pain—Capecitabine—prostate cancer	5.52e-05	0.000219	CcSEcCtD
Naratriptan—Constipation—Capecitabine—prostate cancer	5.52e-05	0.000219	CcSEcCtD
Naratriptan—Erythema—Epirubicin—prostate cancer	5.51e-05	0.000219	CcSEcCtD
Naratriptan—Feeling abnormal—Docetaxel—prostate cancer	5.49e-05	0.000218	CcSEcCtD
Naratriptan—Diarrhoea—Etoposide—prostate cancer	5.49e-05	0.000218	CcSEcCtD
Naratriptan—Tinnitus—Doxorubicin—prostate cancer	5.46e-05	0.000217	CcSEcCtD
Naratriptan—Cardiac disorder—Doxorubicin—prostate cancer	5.44e-05	0.000216	CcSEcCtD
Naratriptan—Feeling abnormal—Capecitabine—prostate cancer	5.32e-05	0.000211	CcSEcCtD
Naratriptan—Angiopathy—Doxorubicin—prostate cancer	5.31e-05	0.000211	CcSEcCtD
Naratriptan—Dizziness—Etoposide—prostate cancer	5.31e-05	0.000211	CcSEcCtD
Naratriptan—Muscle spasms—Epirubicin—prostate cancer	5.3e-05	0.00021	CcSEcCtD
Naratriptan—Immune system disorder—Doxorubicin—prostate cancer	5.29e-05	0.00021	CcSEcCtD
Naratriptan—Body temperature increased—Docetaxel—prostate cancer	5.27e-05	0.000209	CcSEcCtD
Naratriptan—Chills—Doxorubicin—prostate cancer	5.26e-05	0.000209	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Prednisone—prostate cancer	5.24e-05	0.000208	CcSEcCtD
Naratriptan—Arrhythmia—Doxorubicin—prostate cancer	5.23e-05	0.000208	CcSEcCtD
Naratriptan—Vision blurred—Epirubicin—prostate cancer	5.19e-05	0.000206	CcSEcCtD
Naratriptan—Alopecia—Doxorubicin—prostate cancer	5.18e-05	0.000206	CcSEcCtD
Naratriptan—Paraesthesia—Prednisone—prostate cancer	5.16e-05	0.000205	CcSEcCtD
Naratriptan—Urticaria—Capecitabine—prostate cancer	5.13e-05	0.000204	CcSEcCtD
Naratriptan—Ill-defined disorder—Epirubicin—prostate cancer	5.11e-05	0.000203	CcSEcCtD
Naratriptan—Body temperature increased—Capecitabine—prostate cancer	5.1e-05	0.000203	CcSEcCtD
Naratriptan—Vomiting—Etoposide—prostate cancer	5.1e-05	0.000203	CcSEcCtD
Naratriptan—Erythema—Doxorubicin—prostate cancer	5.1e-05	0.000202	CcSEcCtD
Naratriptan—Anaemia—Epirubicin—prostate cancer	5.09e-05	0.000202	CcSEcCtD
Naratriptan—Agitation—Epirubicin—prostate cancer	5.06e-05	0.000201	CcSEcCtD
Naratriptan—Rash—Etoposide—prostate cancer	5.06e-05	0.000201	CcSEcCtD
Naratriptan—Dermatitis—Etoposide—prostate cancer	5.05e-05	0.000201	CcSEcCtD
Naratriptan—Headache—Etoposide—prostate cancer	5.03e-05	0.0002	CcSEcCtD
Naratriptan—Malaise—Epirubicin—prostate cancer	4.97e-05	0.000197	CcSEcCtD
Naratriptan—Fatigue—Prednisone—prostate cancer	4.96e-05	0.000197	CcSEcCtD
Naratriptan—Vertigo—Epirubicin—prostate cancer	4.95e-05	0.000197	CcSEcCtD
Naratriptan—Syncope—Epirubicin—prostate cancer	4.94e-05	0.000196	CcSEcCtD
Naratriptan—Constipation—Prednisone—prostate cancer	4.92e-05	0.000195	CcSEcCtD
Naratriptan—Hypersensitivity—Docetaxel—prostate cancer	4.91e-05	0.000195	CcSEcCtD
Naratriptan—Muscle spasms—Doxorubicin—prostate cancer	4.9e-05	0.000195	CcSEcCtD
Naratriptan—Palpitations—Epirubicin—prostate cancer	4.87e-05	0.000193	CcSEcCtD
Naratriptan—Loss of consciousness—Epirubicin—prostate cancer	4.84e-05	0.000192	CcSEcCtD
Naratriptan—Cough—Epirubicin—prostate cancer	4.81e-05	0.000191	CcSEcCtD
Naratriptan—Vision blurred—Doxorubicin—prostate cancer	4.81e-05	0.000191	CcSEcCtD
Naratriptan—Asthenia—Docetaxel—prostate cancer	4.78e-05	0.00019	CcSEcCtD
Naratriptan—Convulsion—Epirubicin—prostate cancer	4.77e-05	0.00019	CcSEcCtD
Naratriptan—Nausea—Etoposide—prostate cancer	4.77e-05	0.000189	CcSEcCtD
Naratriptan—Hypersensitivity—Capecitabine—prostate cancer	4.76e-05	0.000189	CcSEcCtD
Naratriptan—Feeling abnormal—Prednisone—prostate cancer	4.74e-05	0.000188	CcSEcCtD
Naratriptan—Ill-defined disorder—Doxorubicin—prostate cancer	4.73e-05	0.000188	CcSEcCtD
Naratriptan—Pruritus—Docetaxel—prostate cancer	4.72e-05	0.000187	CcSEcCtD
Naratriptan—Anaemia—Doxorubicin—prostate cancer	4.71e-05	0.000187	CcSEcCtD
Naratriptan—Arthralgia—Epirubicin—prostate cancer	4.69e-05	0.000186	CcSEcCtD
Naratriptan—Myalgia—Epirubicin—prostate cancer	4.69e-05	0.000186	CcSEcCtD
Naratriptan—Agitation—Doxorubicin—prostate cancer	4.69e-05	0.000186	CcSEcCtD
Naratriptan—Anxiety—Epirubicin—prostate cancer	4.68e-05	0.000186	CcSEcCtD
Naratriptan—Discomfort—Epirubicin—prostate cancer	4.64e-05	0.000184	CcSEcCtD
Naratriptan—Asthenia—Capecitabine—prostate cancer	4.63e-05	0.000184	CcSEcCtD
Naratriptan—Malaise—Doxorubicin—prostate cancer	4.6e-05	0.000183	CcSEcCtD
Naratriptan—Dry mouth—Epirubicin—prostate cancer	4.59e-05	0.000182	CcSEcCtD
Naratriptan—Vertigo—Doxorubicin—prostate cancer	4.58e-05	0.000182	CcSEcCtD
Naratriptan—Syncope—Doxorubicin—prostate cancer	4.57e-05	0.000182	CcSEcCtD
Naratriptan—Urticaria—Prednisone—prostate cancer	4.57e-05	0.000181	CcSEcCtD
Naratriptan—Pruritus—Capecitabine—prostate cancer	4.57e-05	0.000181	CcSEcCtD
Naratriptan—Diarrhoea—Docetaxel—prostate cancer	4.56e-05	0.000181	CcSEcCtD
Naratriptan—Body temperature increased—Prednisone—prostate cancer	4.55e-05	0.000181	CcSEcCtD
Naratriptan—Confusional state—Epirubicin—prostate cancer	4.53e-05	0.00018	CcSEcCtD
Naratriptan—Palpitations—Doxorubicin—prostate cancer	4.51e-05	0.000179	CcSEcCtD
Naratriptan—Oedema—Epirubicin—prostate cancer	4.5e-05	0.000179	CcSEcCtD
Naratriptan—Anaphylactic shock—Epirubicin—prostate cancer	4.5e-05	0.000179	CcSEcCtD
Naratriptan—Loss of consciousness—Doxorubicin—prostate cancer	4.48e-05	0.000178	CcSEcCtD
Naratriptan—Infection—Epirubicin—prostate cancer	4.47e-05	0.000177	CcSEcCtD
Naratriptan—Cough—Doxorubicin—prostate cancer	4.45e-05	0.000177	CcSEcCtD
Naratriptan—Shock—Epirubicin—prostate cancer	4.42e-05	0.000176	CcSEcCtD
Naratriptan—Convulsion—Doxorubicin—prostate cancer	4.42e-05	0.000175	CcSEcCtD
Naratriptan—Diarrhoea—Capecitabine—prostate cancer	4.42e-05	0.000175	CcSEcCtD
Naratriptan—Nervous system disorder—Epirubicin—prostate cancer	4.41e-05	0.000175	CcSEcCtD
Naratriptan—Dizziness—Docetaxel—prostate cancer	4.41e-05	0.000175	CcSEcCtD
Naratriptan—Thrombocytopenia—Epirubicin—prostate cancer	4.4e-05	0.000175	CcSEcCtD
Naratriptan—Skin disorder—Epirubicin—prostate cancer	4.37e-05	0.000173	CcSEcCtD
Naratriptan—Hyperhidrosis—Epirubicin—prostate cancer	4.35e-05	0.000173	CcSEcCtD
Naratriptan—Arthralgia—Doxorubicin—prostate cancer	4.34e-05	0.000172	CcSEcCtD
Naratriptan—Myalgia—Doxorubicin—prostate cancer	4.34e-05	0.000172	CcSEcCtD
Naratriptan—Anxiety—Doxorubicin—prostate cancer	4.33e-05	0.000172	CcSEcCtD
Naratriptan—Discomfort—Doxorubicin—prostate cancer	4.29e-05	0.00017	CcSEcCtD
Naratriptan—Dizziness—Capecitabine—prostate cancer	4.27e-05	0.00017	CcSEcCtD
Naratriptan—Dry mouth—Doxorubicin—prostate cancer	4.25e-05	0.000169	CcSEcCtD
Naratriptan—Vomiting—Docetaxel—prostate cancer	4.24e-05	0.000168	CcSEcCtD
Naratriptan—Hypersensitivity—Prednisone—prostate cancer	4.24e-05	0.000168	CcSEcCtD
Naratriptan—Rash—Docetaxel—prostate cancer	4.2e-05	0.000167	CcSEcCtD
Naratriptan—Hypotension—Epirubicin—prostate cancer	4.2e-05	0.000167	CcSEcCtD
Naratriptan—Dermatitis—Docetaxel—prostate cancer	4.2e-05	0.000167	CcSEcCtD
Naratriptan—Confusional state—Doxorubicin—prostate cancer	4.2e-05	0.000167	CcSEcCtD
Naratriptan—Headache—Docetaxel—prostate cancer	4.18e-05	0.000166	CcSEcCtD
Naratriptan—Anaphylactic shock—Doxorubicin—prostate cancer	4.16e-05	0.000165	CcSEcCtD
Naratriptan—Oedema—Doxorubicin—prostate cancer	4.16e-05	0.000165	CcSEcCtD
Naratriptan—Infection—Doxorubicin—prostate cancer	4.13e-05	0.000164	CcSEcCtD
Naratriptan—Asthenia—Prednisone—prostate cancer	4.13e-05	0.000164	CcSEcCtD
Naratriptan—Vomiting—Capecitabine—prostate cancer	4.1e-05	0.000163	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.1e-05	0.000163	CcSEcCtD
Naratriptan—Shock—Doxorubicin—prostate cancer	4.09e-05	0.000163	CcSEcCtD
Naratriptan—Nervous system disorder—Doxorubicin—prostate cancer	4.08e-05	0.000162	CcSEcCtD
Naratriptan—Thrombocytopenia—Doxorubicin—prostate cancer	4.07e-05	0.000162	CcSEcCtD
Naratriptan—Rash—Capecitabine—prostate cancer	4.07e-05	0.000162	CcSEcCtD
Naratriptan—Pruritus—Prednisone—prostate cancer	4.07e-05	0.000162	CcSEcCtD
Naratriptan—Dermatitis—Capecitabine—prostate cancer	4.07e-05	0.000161	CcSEcCtD
Naratriptan—Headache—Capecitabine—prostate cancer	4.04e-05	0.000161	CcSEcCtD
Naratriptan—Skin disorder—Doxorubicin—prostate cancer	4.04e-05	0.000161	CcSEcCtD
Naratriptan—Paraesthesia—Epirubicin—prostate cancer	4.04e-05	0.00016	CcSEcCtD
Naratriptan—Hyperhidrosis—Doxorubicin—prostate cancer	4.02e-05	0.00016	CcSEcCtD
Naratriptan—Dyspnoea—Epirubicin—prostate cancer	4.01e-05	0.000159	CcSEcCtD
Naratriptan—Somnolence—Epirubicin—prostate cancer	4e-05	0.000159	CcSEcCtD
Naratriptan—Nausea—Docetaxel—prostate cancer	3.96e-05	0.000157	CcSEcCtD
Naratriptan—Diarrhoea—Prednisone—prostate cancer	3.93e-05	0.000156	CcSEcCtD
Naratriptan—Hypotension—Doxorubicin—prostate cancer	3.89e-05	0.000154	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Epirubicin—prostate cancer	3.88e-05	0.000154	CcSEcCtD
Naratriptan—Fatigue—Epirubicin—prostate cancer	3.88e-05	0.000154	CcSEcCtD
Naratriptan—Pain—Epirubicin—prostate cancer	3.85e-05	0.000153	CcSEcCtD
Naratriptan—Constipation—Epirubicin—prostate cancer	3.85e-05	0.000153	CcSEcCtD
Naratriptan—Nausea—Capecitabine—prostate cancer	3.83e-05	0.000152	CcSEcCtD
Naratriptan—Dizziness—Prednisone—prostate cancer	3.8e-05	0.000151	CcSEcCtD
Naratriptan—Musculoskeletal discomfort—Doxorubicin—prostate cancer	3.79e-05	0.000151	CcSEcCtD
Naratriptan—Paraesthesia—Doxorubicin—prostate cancer	3.74e-05	0.000148	CcSEcCtD
Naratriptan—Dyspnoea—Doxorubicin—prostate cancer	3.71e-05	0.000147	CcSEcCtD
Naratriptan—Feeling abnormal—Epirubicin—prostate cancer	3.71e-05	0.000147	CcSEcCtD
Naratriptan—Somnolence—Doxorubicin—prostate cancer	3.7e-05	0.000147	CcSEcCtD
Naratriptan—Vomiting—Prednisone—prostate cancer	3.66e-05	0.000145	CcSEcCtD
Naratriptan—Rash—Prednisone—prostate cancer	3.63e-05	0.000144	CcSEcCtD
Naratriptan—Dermatitis—Prednisone—prostate cancer	3.62e-05	0.000144	CcSEcCtD
Naratriptan—Headache—Prednisone—prostate cancer	3.6e-05	0.000143	CcSEcCtD
Naratriptan—Gastrointestinal disorder—Doxorubicin—prostate cancer	3.59e-05	0.000143	CcSEcCtD
Naratriptan—Fatigue—Doxorubicin—prostate cancer	3.59e-05	0.000142	CcSEcCtD
Naratriptan—Urticaria—Epirubicin—prostate cancer	3.57e-05	0.000142	CcSEcCtD
Naratriptan—Constipation—Doxorubicin—prostate cancer	3.56e-05	0.000141	CcSEcCtD
Naratriptan—Pain—Doxorubicin—prostate cancer	3.56e-05	0.000141	CcSEcCtD
Naratriptan—Body temperature increased—Epirubicin—prostate cancer	3.56e-05	0.000141	CcSEcCtD
Naratriptan—Feeling abnormal—Doxorubicin—prostate cancer	3.43e-05	0.000136	CcSEcCtD
Naratriptan—Nausea—Prednisone—prostate cancer	3.42e-05	0.000136	CcSEcCtD
Naratriptan—Hypersensitivity—Epirubicin—prostate cancer	3.31e-05	0.000132	CcSEcCtD
Naratriptan—Urticaria—Doxorubicin—prostate cancer	3.31e-05	0.000131	CcSEcCtD
Naratriptan—Body temperature increased—Doxorubicin—prostate cancer	3.29e-05	0.000131	CcSEcCtD
Naratriptan—Asthenia—Epirubicin—prostate cancer	3.23e-05	0.000128	CcSEcCtD
Naratriptan—Pruritus—Epirubicin—prostate cancer	3.18e-05	0.000126	CcSEcCtD
Naratriptan—Diarrhoea—Epirubicin—prostate cancer	3.08e-05	0.000122	CcSEcCtD
Naratriptan—Hypersensitivity—Doxorubicin—prostate cancer	3.07e-05	0.000122	CcSEcCtD
Naratriptan—Asthenia—Doxorubicin—prostate cancer	2.99e-05	0.000119	CcSEcCtD
Naratriptan—Dizziness—Epirubicin—prostate cancer	2.97e-05	0.000118	CcSEcCtD
Naratriptan—Pruritus—Doxorubicin—prostate cancer	2.94e-05	0.000117	CcSEcCtD
Naratriptan—Vomiting—Epirubicin—prostate cancer	2.86e-05	0.000114	CcSEcCtD
Naratriptan—Diarrhoea—Doxorubicin—prostate cancer	2.85e-05	0.000113	CcSEcCtD
Naratriptan—Rash—Epirubicin—prostate cancer	2.84e-05	0.000113	CcSEcCtD
Naratriptan—Dermatitis—Epirubicin—prostate cancer	2.83e-05	0.000113	CcSEcCtD
Naratriptan—Headache—Epirubicin—prostate cancer	2.82e-05	0.000112	CcSEcCtD
Naratriptan—Dizziness—Doxorubicin—prostate cancer	2.75e-05	0.000109	CcSEcCtD
Naratriptan—Nausea—Epirubicin—prostate cancer	2.67e-05	0.000106	CcSEcCtD
Naratriptan—Vomiting—Doxorubicin—prostate cancer	2.65e-05	0.000105	CcSEcCtD
Naratriptan—Rash—Doxorubicin—prostate cancer	2.62e-05	0.000104	CcSEcCtD
Naratriptan—Dermatitis—Doxorubicin—prostate cancer	2.62e-05	0.000104	CcSEcCtD
Naratriptan—Headache—Doxorubicin—prostate cancer	2.61e-05	0.000104	CcSEcCtD
Naratriptan—Nausea—Doxorubicin—prostate cancer	2.47e-05	9.82e-05	CcSEcCtD
Naratriptan—MAOA—Metabolism—CYP1A1—prostate cancer	1.22e-05	0.000159	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—JAK2—prostate cancer	1.22e-05	0.000158	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—ERCC2—prostate cancer	1.21e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL12—prostate cancer	1.21e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LPL—prostate cancer	1.21e-05	0.000157	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—FGF2—prostate cancer	1.2e-05	0.000156	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—IL2—prostate cancer	1.2e-05	0.000155	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PDGFRB—prostate cancer	1.2e-05	0.000155	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—NOS3—prostate cancer	1.19e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CB—prostate cancer	1.19e-05	0.000154	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LPL—prostate cancer	1.18e-05	0.000153	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—IL2—prostate cancer	1.17e-05	0.000152	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PDGFRB—prostate cancer	1.17e-05	0.000152	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ITGB3—prostate cancer	1.17e-05	0.000151	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CB—prostate cancer	1.16e-05	0.00015	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CG—prostate cancer	1.15e-05	0.00015	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—JAK2—prostate cancer	1.15e-05	0.000149	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ITGB3—prostate cancer	1.14e-05	0.000148	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—MTHFR—prostate cancer	1.14e-05	0.000148	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASP9—prostate cancer	1.14e-05	0.000148	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—CXCL8—prostate cancer	1.14e-05	0.000148	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ERBB3—prostate cancer	1.13e-05	0.000147	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—PIK3CA—prostate cancer	1.13e-05	0.000147	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGFR2—prostate cancer	1.13e-05	0.000147	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MDM2—prostate cancer	1.13e-05	0.000146	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PPARA—prostate cancer	1.12e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CD—prostate cancer	1.12e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—CXCL8—prostate cancer	1.12e-05	0.000145	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—ERBB2—prostate cancer	1.11e-05	0.000144	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ERBB3—prostate cancer	1.11e-05	0.000144	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGFR2—prostate cancer	1.11e-05	0.000143	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PRKCQ—prostate cancer	1.11e-05	0.000143	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NGFR—prostate cancer	1.11e-05	0.000143	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CB—prostate cancer	1.1e-05	0.000142	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAP3K7—prostate cancer	1.09e-05	0.000142	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL2—prostate cancer	1.09e-05	0.000141	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TERT—prostate cancer	1.09e-05	0.000141	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL2—prostate cancer	1.07e-05	0.000138	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TERT—prostate cancer	1.06e-05	0.000138	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CAV1—prostate cancer	1.05e-05	0.000137	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CXCL8—prostate cancer	1.05e-05	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF10—prostate cancer	1.05e-05	0.000136	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ADRB2—prostate cancer	1.04e-05	0.000135	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—HIF1A—prostate cancer	1.04e-05	0.000134	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1B—prostate cancer	1.03e-05	0.000133	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—JAK2—prostate cancer	1.03e-05	0.000133	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—MAP2K1—prostate cancer	1.02e-05	0.000132	CbGpPWpGaD
Naratriptan—HTR1F—GPCR downstream signaling—AKT1—prostate cancer	1.02e-05	0.000132	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—HIF1A—prostate cancer	1.02e-05	0.000132	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CD—prostate cancer	1.01e-05	0.000132	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VAV3—prostate cancer	1.01e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—LEP—prostate cancer	1.01e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CASP3—prostate cancer	1.01e-05	0.000131	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL2—prostate cancer	1.01e-05	0.00013	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CAV1—prostate cancer	1e-05	0.00013	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—IL6—prostate cancer	1e-05	0.00013	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFBR2—prostate cancer	9.99e-06	0.00013	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KDR—prostate cancer	9.92e-06	0.000129	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—LEP—prostate cancer	9.92e-06	0.000129	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ITPR1—prostate cancer	9.83e-06	0.000127	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CAV1—prostate cancer	9.83e-06	0.000127	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CCND1—prostate cancer	9.81e-06	0.000127	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CB—prostate cancer	9.74e-06	0.000126	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KDR—prostate cancer	9.72e-06	0.000126	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CTNNB1—prostate cancer	9.71e-06	0.000126	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ESR1—prostate cancer	9.67e-06	0.000125	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CG—prostate cancer	9.59e-06	0.000124	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MMP9—prostate cancer	9.52e-06	0.000123	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—CDKN1A—prostate cancer	9.49e-06	0.000123	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ESR1—prostate cancer	9.47e-06	0.000123	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PTEN—prostate cancer	9.47e-06	0.000123	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—BAD—prostate cancer	9.44e-06	0.000122	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IGF1R—prostate cancer	9.4e-06	0.000122	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—CXCL8—prostate cancer	9.36e-06	0.000121	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—JAK2—prostate cancer	9.31e-06	0.000121	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—BAD—prostate cancer	9.24e-06	0.00012	CbGpPWpGaD
Naratriptan—HTR1F—Signaling by GPCR—AKT1—prostate cancer	9.24e-06	0.00012	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CG—prostate cancer	9.14e-06	0.000118	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—APC—prostate cancer	9.14e-06	0.000118	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—INS—prostate cancer	9.08e-06	0.000118	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IRS1—prostate cancer	9.04e-06	0.000117	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGF—prostate cancer	9.04e-06	0.000117	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EP300—prostate cancer	9.03e-06	0.000117	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LPL—prostate cancer	9.01e-06	0.000117	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CG—prostate cancer	8.95e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—APC—prostate cancer	8.95e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—IL2—prostate cancer	8.95e-06	0.000116	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PDGFRB—prostate cancer	8.93e-06	0.000116	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—CREBBP—prostate cancer	8.9e-06	0.000115	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IRS1—prostate cancer	8.85e-06	0.000115	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGF—prostate cancer	8.85e-06	0.000115	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CB—prostate cancer	8.85e-06	0.000115	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—SRC—prostate cancer	8.78e-06	0.000114	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—GSK3B—prostate cancer	8.77e-06	0.000114	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ITGB3—prostate cancer	8.71e-06	0.000113	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—INS—prostate cancer	8.65e-06	0.000112	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—GSK3B—prostate cancer	8.59e-06	0.000111	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—VEGFA—prostate cancer	8.55e-06	0.000111	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—CXCL8—prostate cancer	8.5e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CREBBP—prostate cancer	8.48e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—INS—prostate cancer	8.47e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—STAT3—prostate cancer	8.47e-06	0.00011	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB3—prostate cancer	8.45e-06	0.000109	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CD—prostate cancer	8.43e-06	0.000109	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGFR2—prostate cancer	8.43e-06	0.000109	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IGF1—prostate cancer	8.37e-06	0.000108	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—EGFR—prostate cancer	8.33e-06	0.000108	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CREBBP—prostate cancer	8.3e-06	0.000108	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IGF1—prostate cancer	8.2e-06	0.000106	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—EGFR—prostate cancer	8.16e-06	0.000106	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL2—prostate cancer	8.12e-06	0.000105	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TERT—prostate cancer	8.09e-06	0.000105	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MAP2K1—prostate cancer	8.09e-06	0.000105	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CD—prostate cancer	8.04e-06	0.000104	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—NOS3—prostate cancer	7.96e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—PIK3CA—prostate cancer	7.96e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SERPINE1—prostate cancer	7.95e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MAP2K1—prostate cancer	7.92e-06	0.000103	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CD—prostate cancer	7.87e-06	0.000102	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—KRAS—prostate cancer	7.87e-06	0.000102	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—MYC—prostate cancer	7.87e-06	0.000102	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TGFB1—prostate cancer	7.85e-06	0.000102	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—PIK3CA—prostate cancer	7.79e-06	0.000101	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SERPINE1—prostate cancer	7.78e-06	0.000101	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—HIF1A—prostate cancer	7.74e-06	0.0001	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—KRAS—prostate cancer	7.7e-06	9.99e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—FGF2—prostate cancer	7.7e-06	9.97e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—EGFR—prostate cancer	7.69e-06	9.97e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—NOS3—prostate cancer	7.59e-06	9.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—LEP—prostate cancer	7.56e-06	9.79e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—FGF2—prostate cancer	7.54e-06	9.77e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CAV1—prostate cancer	7.49e-06	9.7e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—NOS3—prostate cancer	7.43e-06	9.63e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KDR—prostate cancer	7.4e-06	9.59e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—JAK2—prostate cancer	7.38e-06	9.56e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CB—prostate cancer	7.35e-06	9.53e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTGS2—prostate cancer	7.28e-06	9.44e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—KRAS—prostate cancer	7.27e-06	9.42e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—PIK3CA—prostate cancer	7.23e-06	9.37e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—JAK2—prostate cancer	7.22e-06	9.36e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ESR1—prostate cancer	7.21e-06	9.35e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MDM2—prostate cancer	7.2e-06	9.33e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—ERBB2—prostate cancer	7.1e-06	9.2e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—PIK3CA—prostate cancer	7.08e-06	9.17e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MDM2—prostate cancer	7.05e-06	9.14e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—BAD—prostate cancer	7.04e-06	9.13e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CB—prostate cancer	7.01e-06	9.08e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—ERBB2—prostate cancer	6.95e-06	9.01e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CB—prostate cancer	6.86e-06	8.89e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—APC—prostate cancer	6.82e-06	8.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CG—prostate cancer	6.82e-06	8.84e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGF—prostate cancer	6.74e-06	8.74e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IRS1—prostate cancer	6.74e-06	8.74e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CXCL8—prostate cancer	6.73e-06	8.73e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—PIK3CA—prostate cancer	6.68e-06	8.66e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CXCL8—prostate cancer	6.59e-06	8.54e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1B—prostate cancer	6.57e-06	8.52e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—GSK3B—prostate cancer	6.54e-06	8.48e-05	CbGpPWpGaD
Naratriptan—HTR1D—GPCR downstream signaling—AKT1—prostate cancer	6.5e-06	8.43e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—TP53—prostate cancer	6.46e-06	8.37e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—INS—prostate cancer	6.46e-06	8.37e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CASP3—prostate cancer	6.44e-06	8.35e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1B—prostate cancer	6.44e-06	8.34e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL2—prostate cancer	6.43e-06	8.34e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—IL6—prostate cancer	6.4e-06	8.3e-05	CbGpPWpGaD
Naratriptan—HTR1B—GPCR downstream signaling—AKT1—prostate cancer	6.37e-06	8.25e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PTEN—prostate cancer	6.35e-06	8.23e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CREBBP—prostate cancer	6.32e-06	8.19e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CASP3—prostate cancer	6.31e-06	8.18e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL2—prostate cancer	6.3e-06	8.16e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CCND1—prostate cancer	6.27e-06	8.13e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—IL6—prostate cancer	6.27e-06	8.12e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IGF1—prostate cancer	6.24e-06	8.09e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—EGFR—prostate cancer	6.21e-06	8.05e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CTNNB1—prostate cancer	6.21e-06	8.05e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CCND1—prostate cancer	6.14e-06	7.96e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MMP9—prostate cancer	6.09e-06	7.89e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CTNNB1—prostate cancer	6.08e-06	7.88e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—CDKN1A—prostate cancer	6.07e-06	7.86e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—EP300—prostate cancer	6.06e-06	7.85e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PTEN—prostate cancer	6.05e-06	7.85e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MAP2K1—prostate cancer	6.03e-06	7.82e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CD—prostate cancer	6e-06	7.77e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MMP9—prostate cancer	5.96e-06	7.73e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—CDKN1A—prostate cancer	5.94e-06	7.7e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—PIK3CA—prostate cancer	5.94e-06	7.7e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SERPINE1—prostate cancer	5.93e-06	7.68e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PTEN—prostate cancer	5.93e-06	7.68e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—IL6—prostate cancer	5.91e-06	7.66e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling by GPCR—AKT1—prostate cancer	5.91e-06	7.65e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—KRAS—prostate cancer	5.87e-06	7.61e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling by GPCR—AKT1—prostate cancer	5.78e-06	7.49e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EP300—prostate cancer	5.77e-06	7.48e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—FGF2—prostate cancer	5.74e-06	7.44e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—NOS3—prostate cancer	5.66e-06	7.34e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EP300—prostate cancer	5.65e-06	7.33e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—SRC—prostate cancer	5.61e-06	7.28e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—JAK2—prostate cancer	5.5e-06	7.13e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—SRC—prostate cancer	5.5e-06	7.12e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—VEGFA—prostate cancer	5.47e-06	7.09e-05	CbGpPWpGaD
Naratriptan—HTR1F—Signaling Pathways—AKT1—prostate cancer	5.46e-06	7.07e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—STAT3—prostate cancer	5.41e-06	7.02e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—PIK3CA—prostate cancer	5.39e-06	6.99e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MDM2—prostate cancer	5.37e-06	6.96e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—VEGFA—prostate cancer	5.35e-06	6.94e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—STAT3—prostate cancer	5.3e-06	6.87e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—ERBB2—prostate cancer	5.3e-06	6.86e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CB—prostate cancer	5.23e-06	6.77e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—MYC—prostate cancer	5.03e-06	6.52e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CXCL8—prostate cancer	5.02e-06	6.51e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TGFB1—prostate cancer	5.02e-06	6.5e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—MYC—prostate cancer	4.93e-06	6.38e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—EGFR—prostate cancer	4.92e-06	6.38e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TGFB1—prostate cancer	4.91e-06	6.37e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	4.9e-06	6.36e-05	CbGpPWpGaD
Naratriptan—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	4.85e-06	6.29e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—EGFR—prostate cancer	4.82e-06	6.24e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CASP3—prostate cancer	4.81e-06	6.23e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL2—prostate cancer	4.8e-06	6.22e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—IL6—prostate cancer	4.77e-06	6.19e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CCND1—prostate cancer	4.68e-06	6.06e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—KRAS—prostate cancer	4.65e-06	6.02e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	4.63e-06	6e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—KRAS—prostate cancer	4.55e-06	5.9e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MMP9—prostate cancer	4.54e-06	5.89e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	4.53e-06	5.87e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PTEN—prostate cancer	4.52e-06	5.85e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—PIK3CA—prostate cancer	4.48e-06	5.81e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling by GPCR—AKT1—prostate cancer	4.41e-06	5.71e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EP300—prostate cancer	4.31e-06	5.58e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	4.27e-06	5.53e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—SRC—prostate cancer	4.19e-06	5.43e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	4.18e-06	5.42e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—TP53—prostate cancer	4.13e-06	5.35e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—VEGFA—prostate cancer	4.08e-06	5.29e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—TP53—prostate cancer	4.05e-06	5.24e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—STAT3—prostate cancer	4.04e-06	5.23e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—IL6—prostate cancer	3.78e-06	4.9e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—MYC—prostate cancer	3.75e-06	4.86e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TGFB1—prostate cancer	3.74e-06	4.85e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—IL6—prostate cancer	3.7e-06	4.8e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—EGFR—prostate cancer	3.67e-06	4.76e-05	CbGpPWpGaD
Naratriptan—MAOA—Metabolism—AKT1—prostate cancer	3.66e-06	4.74e-05	CbGpPWpGaD
Naratriptan—HTR1D—Signaling Pathways—AKT1—prostate cancer	3.49e-06	4.52e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—KRAS—prostate cancer	3.47e-06	4.49e-05	CbGpPWpGaD
Naratriptan—HTR1B—Signaling Pathways—AKT1—prostate cancer	3.42e-06	4.43e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	3.19e-06	4.13e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—TP53—prostate cancer	3.08e-06	3.99e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—IL6—prostate cancer	2.82e-06	3.66e-05	CbGpPWpGaD
Naratriptan—HTR1A—Signaling Pathways—AKT1—prostate cancer	2.6e-06	3.37e-05	CbGpPWpGaD
